drugset / Trial / NCT01577160

A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia

NCT01577160

Phase 4 Completed 353 enrolled Johnson & Johnson Taiwan Ltd
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness of paliperidone ER for the treatment of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) participants.

Timeline

Start
2008-05
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Paliperidone Unknown 6 mg Oral

Indications